Pulse Biosciences Advances Nanosecond Pulsed Field Ablation Technology with FDA Approvals for Cardiac and Thyroid Cancer Studies
核心洞察
Pulse Biosciences received FDA approval for an investigational device exemption study of its nanosecond pulsed field ablation catheter to treat drug-resistant paroxysmal atrial fibrillation (搜索).
The company launched a collaboration with MD Anderson Cancer Center to investigate its nPulse technology for treating papillary thyroid microcarcinoma (搜索) in a first-in-human clinical feasibility study.
The nanosecond pulsed field ablation technology delivers briefer electrical pulses than existing microsecond systems, potentially offering advantages in reducing tissue damage and improving treatment outcomes.
Pulse Biosciences has secured FDA approval for two pivotal clinical studies evaluating its nanosecond pulsed field ablation (nsPFA) technology across cardiac and oncology applications, marking significant progress in the development of next-generation ablation systems.
Cardiac Ablation Study Advances
The company received FDA approval for an investigational device exemption (IDE) study of its cardiac catheter ablation system to treat drug-resistant paroxysmal atrial fibrillation (搜索). The single-arm, multicenter NANOPULSE-AF study will evaluate the safety and effectiveness of the nPulse ablation catheter (搜索), which delivers nanosecond electrical pulses to treat the heart rhythm condition.
The technology distinguishes itself from existing pulsed field ablation systems by using nanosecond pulses rather than microsecond pulses, potentially offering clinical advantages. The Pulse Biosciences catheter is designed to deliver a complete lesion in a single energy application, which could streamline procedures and improve outcomes.
"Pulsed field ablation has already reshaped how we treat atrial fibrillation (搜索), but its full potential is just emerging," said David Kenigsberg, chief medical officer for electrophysiology. "This IDE represents a critical next step."
The company aims to demonstrate that its nPulse platform can further reduce injury to surrounding tissue, lower total energy delivery, and improve freedom from atrial arrhythmias. Follow-up data from the study is expected in 2026.
Thyroid Cancer Treatment Collaboration
In parallel, Pulse Biosciences announced a research collaboration with The University of Texas MD Anderson Cancer Center to investigate the nPulse Vybrance Percutaneous Electrode System (搜索) for treating thyroid cancers. The FDA has approved the investigational device exemption for this first-in-human clinical feasibility study.
The study will evaluate the use of nsPFA energy to treat papillary thyroid microcarcinoma (搜索), with MD Anderson researchers led by Victoria Banuchi, associate professor of head and neck surgery, examining the safety and effectiveness of the technology. The study is expected to begin in early 2026, enrolling 30 patients across two sites.
"We believe the nonthermal mechanism of action of nsPFA, which limits scarring, fibrosis, and damage to critical surrounding structures, positions our nPulse technology as potentially the ideal treatment for benign and malignant thyroid tumors," said Paul LaViolette, Pulse Biosciences' co-chairman and CEO.
Technology Platform and Regulatory Status
The nPulse Vybrance Percutaneous Electrode System (搜索) includes a percutaneous needle electrode paired with a proprietary console. The device delivers nsPFA energy to remove cellular tissue without damaging noncellular structures or causing thermal necrosis. The system holds 510(k) clearance for soft-tissue ablation in percutaneous and intraoperative surgical procedures and is intended for non-cardiac use.
Preclinical studies are also underway under an existing material transfer agreement to study the technique's potential for treating anaplastic thyroid carcinoma (搜索), among the most lethal cancers with a five-year survival rate below 5%.
Market Context and Competitive Landscape
Pulsed field ablation has generated significant excitement among electrophysiologists who view it as an improvement over older thermal-based ablation approaches due to its potential for safer and faster procedures. The energy pulses form lesions in cardiac tissue (搜索) to disrupt abnormal electrical signals that cause atrial fibrillation (搜索)'s irregular heartbeats.
New PFA devices have driven strong sales growth for Boston Scientific and Medtronic. Johnson & Johnson and Kardium have also introduced PFA systems in the U.S. market, while Abbott received Europe's CE mark for its PFA system in March and expects FDA approval next year.
In thyroid cancer treatment, thermal ablation approaches such as radiofrequency ablation, microwave ablation, and laser ablation have gained traction globally, particularly in Asia and Europe. These methods allow physicians to target small tumors through percutaneous probes, with clinical studies showing effective treatment of select low-risk thyroid cancers and benign nodules with fewer complications and faster recovery compared with surgery.
The development of nonthermal ablation represents an area of intense interest, as pulsed field ablation avoids heat-related risks such as scarring and collateral damage to critical structures like nerves, vessels, and the trachea. While cardiac electrophysiology has driven much of the early development of PFA, its potential in oncology applications is increasingly recognized.